Roche Checks Wallet As Important Avastin Trial Flops
This article was originally published in The Pink Sheet Daily
Executive Summary
Did Roche overpay for Genentech? Closely watched adjuvant trial for colon cancer fails to meet primary endpoint.
You may also be interested in...
Where Does Avastin Go From Here: Moving Beyond The C-08 Failure
ORLANDO, Fla. - The full presentation of the C-08 trial of Roche/Genentech'sAvastin for use as adjuvant therapy in colorectal cancer - a landmark trial that failed to show an advantage for bevacizumab - at the American Society of Clinical Oncology annual meeting gave the sponsors some signs of encouragement
Where Does Avastin Go From Here: Moving Beyond The C-08 Failure
ORLANDO, Fla. - The full presentation of the C-08 trial of Roche/Genentech'sAvastin for use as adjuvant therapy in colorectal cancer - a landmark trial that failed to show an advantage for bevacizumab - at the American Society of Clinical Oncology annual meeting gave the sponsors some signs of encouragement
Genentech Reorganization Signals Shift To New Model Under Roche
Roche’s Soriot will take over as CEO of Genentech, while key members of Genentech’s management will take on advisory roles or depart.